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Roberto Kalil-Filho, MDM ore than 100 years have elapsed since theﬁrst description of human Americantrypanosomiasis by the Brazilian scientist
Carlos Chagas; however, this neglected disease still
poses signiﬁcant challenges to the world’s health
resources, as it affects millions of people and con-
tinues to be a leading cause of death and disability
in endemic regions. Chagas disease (CD) results
from infection by the ﬂagellate protozoan parasite
Trypanosoma cruzi (T. cruzi). The most common
mode of transmission is by contact with contaminated
feces of hematophagous insects of the Triatominae
subfamily, usually associated with poor housing in
rural areas of Latin America. T. cruzi spread also can
occur from the consumption of contaminated food
or drink, from mother to child during pregnancy, after
solid organ transplantation, or following transfusion
of blood products (1,2).
After exposure, there is a short incubation period,
followed by an acute phase characterized by high
parasitemia and by nonspeciﬁc symptoms, which is
usually self-limited even without treatment. After the
resolution of the acute symptoms, the host’s immune
system reduces the parasite load as the chronic phase
begins. The majority of the patients remain asymp-
tomatic with no apparent organ damage for many
years in what is called the indeterminate phase of the
disease. Patients in the chronic phase of CD have
serologic evidence of T. cruzi infection and remain
infected for life. Recent data demonstrate that even
in this group with no apparent myocardial injury as
assessed by conventional methods, myocardial late
gadolinium enhancement can be detected byr), University of São Paulo Medical School,cardiovascular magnetic resonance. This could indi-
cate the presence of early myocardial ﬁbrosis and
inﬂammation (3). Identifying prognostic factors able
to predict disease progression could improve patient
care and spare lives of at-risk patients. Approximately
one-third of infected patients will eventually develop
signiﬁcant cardiovascular or less often digestive
involvement, sometimes years or decades after the
original infection (1,2). Clinical presentation usually
begins with conduction system disease and/or ven-
tricular arrhythmias and may subsequently progress
to dilated cardiomyopathy and congestive heart fail-
ure. Despite the lack of solid evidence-based data,
therapy should generally be instituted according to
guidelines for the management of heart failure pa-
tients, including neurohumoral inhibition, resynch-
ronization therapy, and implantable cardioverter-
deﬁbrillator (4).
Interestingly, amiodarone, frequently used for
arrhythmia control, has been reported to have
activity against T. cruzi (5). A randomized trial com-
paring amiodarone versus implantable cardioverter-
deﬁbrillator for primary prevention of death is
ongoing (6). CD is a main indication for heart trans-
plantation in Latin America, and adequate selection
of receptors and strategies to reduce reactivation of
disease under immunosuppression are responsible
for excellent survival rates, although at considerable
health care costs to society (7).
The knowledge of the pathogenic mechanisms
involved in chronic CD has evolved substantially.
Today, the importance of autoimmunity in triggering
the disease process is regarded as less important. CD
pathogenesis is considered multifactorial, and more
emphasis is placed on the persistence of the parasite
in damaged organs and the resulting interaction be-
tween host and pathogen (8). Additionally, genetic
J A C C V O L . 6 6 , N O . 1 0 , 2 0 1 5 Kalil-Filho
S E P T E M B E R 8 , 2 0 1 5 : 1 1 9 0 – 2 Guest Editor’s Page
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been associated with susceptibility for disease pro-
gression (9,10).
The importance of T. cruzi persistence in the gen-
esis of the disease has stimulated the investigation of
parasite-elimination strategies. Although the tradi-
tional anti-T. cruzi drugs benznidazole and nifurti-
mox are effective during acute and early infection, it
is unknown whether their use during the chronic
phase of the disease, when most diagnoses are made,
will result in clinically relevant outcomes. A recent
systematic review has showed that trypanocidal
drugs for patients with chronic asymptomatic infec-
tion reduced parasite-related outcomes, but the low
quality and inconsistency of the data should be
acknowledged (11). In this sense, the results of the
much-anticipated BENEFIT (BENznidazole Evaluation
For Interrupting Trypanosomiasis) trial evaluating the
effect of benznidazole on cardiac disease progression
in chronic Chagas heart disease patients could help
establish more evidence-based recommendations
(12). Limited efﬁcacy of the available drugs and
frequent side effects leading to decreased patient
compliance are signiﬁcant therapeutic obstacles;
the lack of novel and better treatment options is
clearly a major point to be addressed. Last year,
the results of a randomized trial evaluating efﬁcacy
and safety of posaconazole in comparison with
benznidazole in patients with chronic CD were
published. Unfortunately, despite promising animal
experiments, the use of posaconazole, the ﬁrst new
trypanocidal drug to be evaluated in a clinical trial
in >40 years, resulted in more treatment failures
during follow-up than standard treatment with
benznidazole (13).
Successful vector-control programs with insecti-
cides, health education, improved housing, migration
of the population from rural areas to the cities, and
the implementation of blood donation screening have
resulted in a signiﬁcant reduction of CD burden in
Latin America. The annual incidence of new cases of
T. cruzi infection in the Southern Cone countries was
reduced 94%, from 700,000 in 1990 to 41,200 in 2006
(14). However, eradication of the disease is unlikely
due to the presence of many domestic and wild res-
ervoirs and the existence of various vectors for
T. cruzi. Unfortunately, transmitting insects are still
frequently observed in domestic and peridomestic
areas in parts of Latin America, and additionally,
outbreaks of oral transmission have been reported
with increasing frequency (14,15). Despite the signif-
icant reduction of CD incidence observed in recent
years, there is still a large residual population of
previously infected persons. Estimates point toapproximately 6 to 7 million infected people world-
wide, mainly in Latin America (16).
The epidemiology of CD has changed and is more
complex today. The increased globalization process
recently observed throughout the world has resulted
in increased airline trafﬁc, as well as enhanced social,
cultural, and economic exchanges between different
countries. Globalization and slow economic growth
in Latin America have resulted in a large inﬂux of
immigrants from endemic regions, especially to North
America and Europe, in search of better living con-
ditions. According to the U.S. census data, there were
17 million Latin American immigrants in 2007,
340,000 of whom were potentially infected by
T. cruzi, and approximately 65,000 may develop
symptomatic CD (17). A recent report illustrates the
potential importance of CD in the United States.
Among immigrants evaluated with nonischemic car-
diomyopathy in Los Angeles, approximately 20%
were found to have CD, and this diagnosis was asso-
ciated with a 4-fold increase in mortality during
follow-up (18). Unfortunately, CD awareness among
Latin American immigrants in the United States is
very limited (19).
The global economic burden of CD is substantial.
Conservative estimates point to global costs of $7.19
billion/year and $188.80 billion/lifetime (20). More
than 10% of these costs originate in the United States
and Canada, countries where the disease is not
endemic. A large portion of the burden comes
from lost productivity from cardiovascular disease-
induced early mortality. The estimated costs of CD
exceed those of some other diseases that receive
greater attention from the medical community, such
as cervical and uterine cancers. This adds an eco-
nomic argument for increased global efforts toward
control of CD (20).
The CD research and drug development landscape
has changed extensively in the last 10 years. The
number of investigators actively involved in the ﬁeld
of new drug discovery has increased substantially.
Research funding from philanthropic foundations
and public sources became available. Several public
and private institutions started signiﬁcant research
efforts to discover novel trypanocidal compounds,
including different laboratory consortia funded by
the U.S. National Institutes of Health and by the
European Union, not-for-proﬁt organizations such as
the Drugs for Neglected Diseases initiative, and
pharmaceutical industries in Europe and Japan (21).
New paradigms in collaboration efforts among
different institutions have also been established.
Technological advancements have allowed the
development of faster and better in vitro and in vivo
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pounds, which will hopefully be soon studied in
proof-of-concept studies for CD. On the clinical side,
several research trials have also been implemented
such as the CHAGASAZOL, STOPCHAGAS (A Study of
the Use of Oral Posaconazole in the Treatment of
Asymptomatic Chronic Chagas Disease; NCT01377480)
and BENEFIT trials (21).
Never before has the outlook for new therapeutic
options for CD seemed so promising, but if we are to
overcome the burden imposed by this dreadful dis-
ease that has affected American men for >9,000
years, continued efforts by government and organi-
zations should be exercised.
Efﬁcient vector control strategies and continuous
vigilance for other forms of CD transmission should
be reinforced. The development of new and more
effective drugs and vaccines against T. cruzi should
be actively pursued. Additionally, we, as a society,should strive for the implementation of better health
education for the population at risk and for the
expansion of access to good medical care of infected
patients. The World Health Organization considers
CD 1 of 17 core neglected tropical diseases; however,
CD burden is no longer restricted to the tropical
belt, and we will only be able to control this
now globalized threat if we adequately support
available treatment and prevention strategies, foster
the development of new trypanocidal therapies,
increase awareness of the disease by at-risk pop-
ulations and medical personnel, and, ﬁnally, do not
neglect the care of infected persons.
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